Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation

Hideomi Ichinokawa, Genichiro Ishii, Kanji Nagai, Akikazu Kawase, Junji Yoshida, Mitsuyo Nishimura, Tomoyuki Hishida, Naomi Ogasawara, Katsuya Tsuchihara, Atsushi Ochiai

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Primary mucinous adenocarcinomas are uncommon, and their pathogenesis remains unclear. We recently reported the clinicopathologic characteristics of surgically resected mucinous adenocarcinoma, including the frequent involvement of the left and lower lung and absence of central fibrosis. The present study attempted to clarify the pathogenesis of mucinous adenocarcinoma based on KRAS mutation status. We selected 45 mucinous adenocarcinoma cases from among 2474 surgically resected primary lung adenocarcinomas. Of these, 22 had a KRAS mutation (48.9%), whereas only 7 (15.6%) had an epidermal growth factor receptor mutation, and 2 cases had both mutations. The mucinous adenocarcinomas with KRAS mutations were located in the lower lung lobe significantly more often (P <.05) than were tumors without KRAS mutation. The mucinous adenocarcinoma cases with KRAS mutations also had a significantly lower frequency of nuclear atypia (P <.05). We compared the degree of immunostaining for matrix metalloproteinase-7 (MMP-7), laminin-5, and geminin in the mucinous adenocarcinoma with and without KRAS mutation. The proportion of geminin-positive cells was lower among the cases with a mutation than among those without (0.7% versus 2.1%; P <.05). No significant differences in the extent of staining of the other markers were observed between the groups. The current study clearly demonstrated that mucinous adenocarcinomas with KRAS mutations have clinicopathologic characteristics different from those of mucinous adenocarcinoma without such mutations.

Original languageEnglish
Pages (from-to)2636-2642
Number of pages7
JournalHuman Pathology
Volume44
Issue number12
DOIs
Publication statusPublished - 2013 Dec
Externally publishedYes

Fingerprint

Mucinous Adenocarcinoma
Mutation
Geminin
Adenocarcinoma of lung
Matrix Metalloproteinase 7
Lung
Epidermal Growth Factor Receptor
Fibrosis

Keywords

  • Epidermal growth factor receptor (EGFR)
  • KRAS
  • Mucinous adenocarcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Ichinokawa, H., Ishii, G., Nagai, K., Kawase, A., Yoshida, J., Nishimura, M., ... Ochiai, A. (2013). Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. Human Pathology, 44(12), 2636-2642. https://doi.org/10.1016/j.humpath.2013.05.026

Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. / Ichinokawa, Hideomi; Ishii, Genichiro; Nagai, Kanji; Kawase, Akikazu; Yoshida, Junji; Nishimura, Mitsuyo; Hishida, Tomoyuki; Ogasawara, Naomi; Tsuchihara, Katsuya; Ochiai, Atsushi.

In: Human Pathology, Vol. 44, No. 12, 12.2013, p. 2636-2642.

Research output: Contribution to journalArticle

Ichinokawa, H, Ishii, G, Nagai, K, Kawase, A, Yoshida, J, Nishimura, M, Hishida, T, Ogasawara, N, Tsuchihara, K & Ochiai, A 2013, 'Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation', Human Pathology, vol. 44, no. 12, pp. 2636-2642. https://doi.org/10.1016/j.humpath.2013.05.026
Ichinokawa H, Ishii G, Nagai K, Kawase A, Yoshida J, Nishimura M et al. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. Human Pathology. 2013 Dec;44(12):2636-2642. https://doi.org/10.1016/j.humpath.2013.05.026
Ichinokawa, Hideomi ; Ishii, Genichiro ; Nagai, Kanji ; Kawase, Akikazu ; Yoshida, Junji ; Nishimura, Mitsuyo ; Hishida, Tomoyuki ; Ogasawara, Naomi ; Tsuchihara, Katsuya ; Ochiai, Atsushi. / Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. In: Human Pathology. 2013 ; Vol. 44, No. 12. pp. 2636-2642.
@article{84e606bf396345ef81c489806f096f5c,
title = "Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation",
abstract = "Primary mucinous adenocarcinomas are uncommon, and their pathogenesis remains unclear. We recently reported the clinicopathologic characteristics of surgically resected mucinous adenocarcinoma, including the frequent involvement of the left and lower lung and absence of central fibrosis. The present study attempted to clarify the pathogenesis of mucinous adenocarcinoma based on KRAS mutation status. We selected 45 mucinous adenocarcinoma cases from among 2474 surgically resected primary lung adenocarcinomas. Of these, 22 had a KRAS mutation (48.9{\%}), whereas only 7 (15.6{\%}) had an epidermal growth factor receptor mutation, and 2 cases had both mutations. The mucinous adenocarcinomas with KRAS mutations were located in the lower lung lobe significantly more often (P <.05) than were tumors without KRAS mutation. The mucinous adenocarcinoma cases with KRAS mutations also had a significantly lower frequency of nuclear atypia (P <.05). We compared the degree of immunostaining for matrix metalloproteinase-7 (MMP-7), laminin-5, and geminin in the mucinous adenocarcinoma with and without KRAS mutation. The proportion of geminin-positive cells was lower among the cases with a mutation than among those without (0.7{\%} versus 2.1{\%}; P <.05). No significant differences in the extent of staining of the other markers were observed between the groups. The current study clearly demonstrated that mucinous adenocarcinomas with KRAS mutations have clinicopathologic characteristics different from those of mucinous adenocarcinoma without such mutations.",
keywords = "Epidermal growth factor receptor (EGFR), KRAS, Mucinous adenocarcinoma",
author = "Hideomi Ichinokawa and Genichiro Ishii and Kanji Nagai and Akikazu Kawase and Junji Yoshida and Mitsuyo Nishimura and Tomoyuki Hishida and Naomi Ogasawara and Katsuya Tsuchihara and Atsushi Ochiai",
year = "2013",
month = "12",
doi = "10.1016/j.humpath.2013.05.026",
language = "English",
volume = "44",
pages = "2636--2642",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation

AU - Ichinokawa, Hideomi

AU - Ishii, Genichiro

AU - Nagai, Kanji

AU - Kawase, Akikazu

AU - Yoshida, Junji

AU - Nishimura, Mitsuyo

AU - Hishida, Tomoyuki

AU - Ogasawara, Naomi

AU - Tsuchihara, Katsuya

AU - Ochiai, Atsushi

PY - 2013/12

Y1 - 2013/12

N2 - Primary mucinous adenocarcinomas are uncommon, and their pathogenesis remains unclear. We recently reported the clinicopathologic characteristics of surgically resected mucinous adenocarcinoma, including the frequent involvement of the left and lower lung and absence of central fibrosis. The present study attempted to clarify the pathogenesis of mucinous adenocarcinoma based on KRAS mutation status. We selected 45 mucinous adenocarcinoma cases from among 2474 surgically resected primary lung adenocarcinomas. Of these, 22 had a KRAS mutation (48.9%), whereas only 7 (15.6%) had an epidermal growth factor receptor mutation, and 2 cases had both mutations. The mucinous adenocarcinomas with KRAS mutations were located in the lower lung lobe significantly more often (P <.05) than were tumors without KRAS mutation. The mucinous adenocarcinoma cases with KRAS mutations also had a significantly lower frequency of nuclear atypia (P <.05). We compared the degree of immunostaining for matrix metalloproteinase-7 (MMP-7), laminin-5, and geminin in the mucinous adenocarcinoma with and without KRAS mutation. The proportion of geminin-positive cells was lower among the cases with a mutation than among those without (0.7% versus 2.1%; P <.05). No significant differences in the extent of staining of the other markers were observed between the groups. The current study clearly demonstrated that mucinous adenocarcinomas with KRAS mutations have clinicopathologic characteristics different from those of mucinous adenocarcinoma without such mutations.

AB - Primary mucinous adenocarcinomas are uncommon, and their pathogenesis remains unclear. We recently reported the clinicopathologic characteristics of surgically resected mucinous adenocarcinoma, including the frequent involvement of the left and lower lung and absence of central fibrosis. The present study attempted to clarify the pathogenesis of mucinous adenocarcinoma based on KRAS mutation status. We selected 45 mucinous adenocarcinoma cases from among 2474 surgically resected primary lung adenocarcinomas. Of these, 22 had a KRAS mutation (48.9%), whereas only 7 (15.6%) had an epidermal growth factor receptor mutation, and 2 cases had both mutations. The mucinous adenocarcinomas with KRAS mutations were located in the lower lung lobe significantly more often (P <.05) than were tumors without KRAS mutation. The mucinous adenocarcinoma cases with KRAS mutations also had a significantly lower frequency of nuclear atypia (P <.05). We compared the degree of immunostaining for matrix metalloproteinase-7 (MMP-7), laminin-5, and geminin in the mucinous adenocarcinoma with and without KRAS mutation. The proportion of geminin-positive cells was lower among the cases with a mutation than among those without (0.7% versus 2.1%; P <.05). No significant differences in the extent of staining of the other markers were observed between the groups. The current study clearly demonstrated that mucinous adenocarcinomas with KRAS mutations have clinicopathologic characteristics different from those of mucinous adenocarcinoma without such mutations.

KW - Epidermal growth factor receptor (EGFR)

KW - KRAS

KW - Mucinous adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84888067635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888067635&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2013.05.026

DO - 10.1016/j.humpath.2013.05.026

M3 - Article

VL - 44

SP - 2636

EP - 2642

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 12

ER -